{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T13:46:24Z","timestamp":1758980784452},"reference-count":43,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,15]]},"DOI":"10.7759\/cureus.47085","type":"journal-article","created":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T04:59:31Z","timestamp":1697432371000},"source":"Crossref","is-referenced-by-count":1,"title":["A Case of Hairy Cell Leukemia Variant: Literature Analysis With Focus on Unmet Needs"],"prefix":"10.7759","author":[{"given":"Amitabh","family":"Kumar Upadhyay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manoj","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anil","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shashank","family":"Shekhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reetal","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1177\/20406207221090886","article-title":"Updates in hairy cell leukemia (HCL) and variant-type HCL (HCL-V): rationale for targeted treatments with a focus on ibrutinib","volume":"13","author":"Paillassa J","year":"2022","unstructured":"Paillassa J, Safa F, Troussard X. Updates in hairy cell leukemia (HCL) and variant-type HCL (HCL-V): rationale for targeted treatments with a focus on ibrutinib. Ther Adv Hematol. 2022, 13:10.1177\/20406207221090886","journal-title":"Ther Adv Hematol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S242247","article-title":"Current and emerging therapeutic options for hairy cell leukemia variant","volume":"14","author":"Liu Q","year":"2021","unstructured":"Liu Q, Harris N, Epperla N, Andritsos LA. Current and emerging therapeutic options for hairy cell leukemia variant. Onco Targets Ther. 2021, 14:1797-805. 10.2147\/OTT.S242247","journal-title":"Onco Targets Ther"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2810","article-title":"Ibrutinib in relapsed hairy cell leukemia variant: a case report and review of the literature","volume":"38","author":"Visentin A","year":"2020","unstructured":"Visentin A, Imbergamo S, Trimarco V, et al.. Ibrutinib in relapsed hairy cell leukemia variant: a case report and review of the literature. Hematol Oncol. 2020, 38:823-6. 10.1002\/hon.2810","journal-title":"Hematol Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.24976","article-title":"Remarkable response of hairy cell leukemia variant to single-agent cladribine","volume":"14","author":"Otieno SB","year":"2022","unstructured":"Otieno SB, Ogbeide O. Remarkable response of hairy cell leukemia variant to single-agent cladribine. Cureus. 2022, 14:e24976. 10.7759\/cureus.24976","journal-title":"Cureus"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/0145-2126(80)90066-1","article-title":"A chronic lymphoproliferative disorder with distinctive features: a distinct variant of hairy-cell leukaemia","author":"Cawley JC","year":"1980","unstructured":"Cawley JC, Burns GF, Hayhoe FG. A chronic lymphoproliferative disorder with distinctive features: a distinct variant of hairy-cell leukaemia. Leuk Res. 1980, 547-59. 10.1016\/0145-2126(80)90066-1","journal-title":"Leuk Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005039","article-title":"Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant","volume":"5","author":"Chihara D","year":"2021","unstructured":"Chihara D, Arons E, Stetler-Stevenson M, et al.. Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant. Blood Adv. 2021, 5:4807-16. 10.1182\/bloodadvances.2021005039","journal-title":"Blood Adv"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401999","article-title":"The natural history and clinico-pathological features of the variant form of hairy cell leukemia","volume":"15","author":"Matutes E","year":"2001","unstructured":"Matutes E, Wotherspoon A, Brito-Babapulle V, Catovsky D. The natural history and clinico-pathological features of the variant form of hairy cell leukemia. Leukemia. 2001, 15:184-6. 10.1038\/sj.leu.2401999","journal-title":"Leukemia"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V76.1.157.157","article-title":"A variant form of hairy cell leukemia resistant to alpha-interferon: clinical and phenotypic characteristics of 17 patients","volume":"76","author":"Sainati L","year":"1990","unstructured":"Sainati L, Matutes E, Mulligan S, de Oliveira MP, Rani S, Lampert IA, Catovsky D. A variant form of hairy cell leukemia resistant to alpha-interferon: clinical and phenotypic characteristics of 17 patients. Blood. 1990, 76:157-62. 10.1182\/blood.V76.1.157.157","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.293","article-title":"Late extramedullary relapse after allogeneic transplantation in a case of variant hairy cell leukaemia","volume":"45","author":"Busemann C","year":"2010","unstructured":"Busemann C, Sch\u00fcler F, Kr\u00fcger W, Kiefer T, Wuppermann M, Androshchuk M, D\u00f6lken G. Late extramedullary relapse after allogeneic transplantation in a case of variant hairy cell leukaemia. Bone Marrow Transplant. 2010, 45:1117-8. 10.1038\/bmt.2009.293","journal-title":"Bone Marrow Transplant"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3109\/10428199709051790","article-title":"Remission in hairy cell leukemia-variant following splenic radiotherapy alone","volume":"26","author":"Sgarabotto D","year":"1997","unstructured":"Sgarabotto D, Vianello F, Radossi P, et al.. Remission in hairy cell leukemia-variant following splenic radiotherapy alone. Leuk Lymphoma. 1997, 26:395-8. 10.3109\/10428199709051790","journal-title":"Leuk Lymphoma"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1159\/000115785","article-title":"Effective treatment of a refractory hairy cell leukemia variant with splenic pre-irradiation and alemtuzumab","volume":"119","author":"Sasaki M","year":"2008","unstructured":"Sasaki M, Sugimoto K, Mori T, Karasawa K, Oshimi K. Effective treatment of a refractory hairy cell leukemia variant with splenic pre-irradiation and alemtuzumab. Acta Haematol. 2008, 119:48-53. 10.1159\/000115785","journal-title":"Acta Haematol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.21304","article-title":"Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: a report of three cases","volume":"8","author":"Visentin A","year":"2017","unstructured":"Visentin A, Imbergamo S, Frezzato F, et al.. Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: a report of three cases. Oncotarget. 2017, 8:110727-31. 10.18632\/oncotarget.21304","journal-title":"Oncotarget"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-351502","article-title":"Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia","volume":"118","author":"Ravandi F","year":"2011","unstructured":"Ravandi F, O'Brien S, Jorgensen J, et al.. Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia. Blood. 2011, 118:3818-23. 10.1182\/blood-2011-04-351502","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.565841","article-title":"Molecular variant of hairy cell leukemia with poor prognosis","volume":"52 Suppl 2","author":"Arons E","year":"2011","unstructured":"Arons E, Kreitman RJ. Molecular variant of hairy cell leukemia with poor prognosis. Leuk Lymphoma. 2011, 52 Suppl 2:99-102. 10.3109\/10428194.2011.565841","journal-title":"Leuk Lymphoma"},{"key":"ref15","article-title":"Cladribine (2-chlorodeoxyadenosine) therapy in hairy cell leukemia variant. A report of three cases","volume":"87","author":"Palomera L","year":"2002","unstructured":"Palomera L, Domingo JM, Sola C, Azaceta G, Calvo MT, Gutierrez M. Cladribine (2-chlorodeoxyadenosine) therapy in hairy cell leukemia variant. A report of three cases. Haematologica. 2002, 87:107-8.","journal-title":"Haematologica"},{"key":"ref16","article-title":"Clinical and molecular complete remission in a case of variant hairy cell leukemia treated with DHAP followed by high-dose chemotherapy plus rituximab","volume":"89","author":"Goldaniga M","year":"2004","unstructured":"Goldaniga M, Guffanti A, Gianelli U, Magni M, Deliliers GL, Baldini L. Clinical and molecular complete remission in a case of variant hairy cell leukemia treated with DHAP followed by high-dose chemotherapy plus rituximab. Haematologica. 2004, 89:ECR41.","journal-title":"Haematologica"},{"key":"ref17","article-title":"Complete remission of hairy cell leukemia variant (HCL-v) complicated by red cell aplasia post treatment with rituximab","volume":"90 Suppl","author":"Quach H","year":"2005","unstructured":"Quach H, Januszewicz H, Westerman D. Complete remission of hairy cell leukemia variant (HCL-v) complicated by red cell aplasia post treatment with rituximab. Haematologica. 2005, 90 Suppl:ECR26.","journal-title":"Haematologica"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1080\/10428190500083433","article-title":"Successful treatment of hairy cell leukemia variant with rituximab","volume":"46","author":"Narat S","year":"2005","unstructured":"Narat S, Gandla J, Dogan A, Mehta A. Successful treatment of hairy cell leukemia variant with rituximab. Leuk Lymphoma. 2005, 46:1229-32. 10.1080\/10428190500083433","journal-title":"Leuk Lymphoma"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.5858\/2005-129-395-HCLVWF","article-title":"Hairy cell leukemia variant with features of intrasinusoidal bone marrow involvement","volume":"129","author":"Ya-In C","year":"2005","unstructured":"Ya-In C, Brandwein J, Pantalony D, Chang H. Hairy cell leukemia variant with features of intrasinusoidal bone marrow involvement. Arch Pathol Lab Med. 2005, 129:395-8. 10.5858\/2005-129-395-HCLVWF","journal-title":"Arch Pathol Lab Med"},{"key":"ref20","article-title":"Hairy cell leukemia-variant--a case report","volume":"48","author":"Gupta K","year":"2005","unstructured":"Gupta K, Jasmina A, Malhotra P, et al.. Hairy cell leukemia-variant--a case report. Indian J Pathol Microbiol. 2005, 48:387-9.","journal-title":"Indian J Pathol Microbiol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1556\/OH.2007.28169","article-title":"Successful alemtuzumab treatment of a patient with atypical hairy cell leukaemia variant (Artice in Hungarian)","volume":"148","author":"Telek B","year":"2007","unstructured":"Telek B, Bat\u00e1r P, Udvardy M. Successful alemtuzumab treatment of a patient with atypical hairy cell leukaemia variant (Artice in Hungarian). Orv Hetil. 2007, 148:1805-7. 10.1556\/OH.2007.28169","journal-title":"Orv Hetil"},{"key":"ref22","article-title":"Rituximab in the treatment of the variant of hairy cell leukaemia: a case report","volume":"29","author":"Hadzi-Pecova L","year":"2008","unstructured":"Hadzi-Pecova L, Stojanovik A, Petrusevska G, Panovska I. Rituximab in the treatment of the variant of hairy cell leukaemia: a case report. Prilozi. 2008, 29:355-60.","journal-title":"Prilozi"},{"key":"ref23","article-title":"Hairy cell leukemia and variant in Taiwan: report of a variant case and literature review","volume":"4","author":"Hsieh YC","year":"2011","unstructured":"Hsieh YC, Chang ST, Chuang SS, Lu CL, Tsao CJ, Lin CN, Li CY. Hairy cell leukemia and variant in Taiwan: report of a variant case and literature review. Int J Clin Exp Pathol. 2011, 4:183-9.","journal-title":"Int J Clin Exp Pathol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s12308-010-0077-1","article-title":"Hairy cell leukemia variant","volume":"4","author":"Kanellis G","year":"2011","unstructured":"Kanellis G, Garcia-Alonso L, Camacho FI, et al.. Hairy cell leukemia variant. J Hematopathol. 2011, 4:13-6. 10.1007\/s12308-010-0077-1","journal-title":"J Hematopathol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.7860\/JCDR\/2013\/5169.2768","article-title":"A hairy cell leukaemia variant - a rare case report","volume":"7","author":"Pande P","year":"2013","unstructured":"Pande P, Yelikar BR, Kumar U M. A hairy cell leukaemia variant - a rare case report. J Clin Diagn Res. 2013, 7:358-60. 10.7860\/JCDR\/2013\/5169.2768","journal-title":"J Clin Diagn Res"},{"key":"ref26","article-title":"A case of hairy cell leukemia variant","volume":"56","author":"Amelia MG","year":"2015","unstructured":"Amelia MG, Camelia D, Mihnea AG. A case of hairy cell leukemia variant. Rom J Morphol Embryol. 2015, 56:553-6.","journal-title":"Rom J Morphol Embryol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjhh.2015.01.003","article-title":"Hairy cell leukemia variant: the importance of differential diagnosis","volume":"37","author":"Rudolf-Oliveira RC","year":"2015","unstructured":"Rudolf-Oliveira RC, Pirolli MM, de Souza FS, Michels J, Santos-Silva MC. Hairy cell leukemia variant: the importance of differential diagnosis. Rev Bras Hematol Hemoter. 2015, 37:132-5. 10.1016\/j.bjhh.2015.01.003","journal-title":"Rev Bras Hematol Hemoter"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1159\/000446696","article-title":"A unique hairy cell leukemia variant","volume":"9","author":"Jian C","year":"2016","unstructured":"Jian C, Hsia CC. A unique hairy cell leukemia variant. Case Rep Oncol. 2016, 9:312-6. 10.1159\/000446696","journal-title":"Case Rep Oncol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.18535\/jmscr\/v5i9.32","article-title":"Hairy cell leukemia - variant (HCL-V): a separate entity","volume":"5","author":"Kapoor AK","year":"2017","unstructured":"Kapoor AK, Kamal J, Singh A, Singh P. Hairy cell leukemia - variant (HCL-V): a separate entity. J Med Sci Clin Res. 2017, 5:10.18535\/jmscr\/v5i9.32","journal-title":"J Med Sci Clin Res"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2017.03.85","article-title":"Hairy cell leukaemia variant with periarticular joint infiltration and excellent radiotherapy response","volume":"5","author":"McKay MJ","year":"2017","unstructured":"McKay MJ, Rady KL, McKay TA. Hairy cell leukaemia variant with periarticular joint infiltration and excellent radiotherapy response. Ann Transl Med. 2017, 5:162. 10.21037\/atm.2017.03.85","journal-title":"Ann Transl Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1239262","article-title":"Ibrutinib for relapsed refractory hairy cell leukemia variant","volume":"58","author":"Bohn JP","year":"2017","unstructured":"Bohn JP, Wanner D, Steurer M. Ibrutinib for relapsed refractory hairy cell leukemia variant. Leuk Lymphoma. 2017, 58:1224-6. 10.1080\/10428194.2016.1239262","journal-title":"Leuk Lymphoma"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25264","article-title":"Biclonal IGHV-4-34 hairy cell leukemia variant and CLL - successful treatment with ibrutinib and venetoclax","volume":"93","author":"Jain P","year":"2018","unstructured":"Jain P, Kanagal-Shamanna R, Konoplev S, Zuo Z, Estrov Z. Biclonal IGHV-4-34 hairy cell leukemia variant and CLL - successful treatment with ibrutinib and venetoclax. Am J Hematol. 2018, 93:1568-9. 10.1002\/ajh.25264","journal-title":"Am J Hematol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1365853","article-title":"Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia","volume":"59","author":"Andritsos LA","year":"2018","unstructured":"Andritsos LA, Grieselhuber NR, Anghelina M, et al.. Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia. Leuk Lymphoma. 2018, 59:1008-11. 10.1080\/10428194.2017.1365853","journal-title":"Leuk Lymphoma"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.2176","article-title":"Variant form of hairy cell leukemia","volume":"7","author":"Wiber M","year":"2019","unstructured":"Wiber M, Maitre E, Cornet E, Sala\u00fcn V, Naguib D, Troussard X. Variant form of hairy cell leukemia. Clin Case Rep. 2019, 7:1161-6. 10.1002\/ccr3.2176","journal-title":"Clin Case Rep"},{"key":"ref35","article-title":"High curative potential of ibrutinib in hairy cell leukemia variant refractory to conventional chemotherapy: a case report","volume":"5","author":"Passucci M","year":"2022","unstructured":"Passucci M, Ligia S, Giudice I, et al.. High curative potential of ibrutinib in hairy cell leukemia variant refractory to conventional chemotherapy: a case report. Hematol Oncol Curr Res. 2022, 5:1018.","journal-title":"Hematol Oncol Curr Res"},{"key":"ref36","article-title":"A case of variant hairy cell leukaemia in durable complete remission on combination therapy","volume":"6","author":"Khan A","year":"2023","unstructured":"Khan A, Krishna V, Reddy DN . A case of variant hairy cell leukaemia in durable complete remission on combination therapy. Clin Oncol Case Rep. 2023, 6:","journal-title":"Clin Oncol Case Rep"},{"key":"ref37","article-title":"Hairy cell leukemia variant: a morphologic, immunologic and clinical study of 7 cases","volume":"75","author":"Zinzani PL","year":"1990","unstructured":"Zinzani PL, Lauria F, Buzzi M, et al.. Hairy cell leukemia variant: a morphologic, immunologic and clinical study of 7 cases. Haematologica. 1990, 75:54-7.","journal-title":"Haematologica"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1999.tb01114.x","article-title":"2-Chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland","volume":"62","author":"Robak T","year":"1999","unstructured":"Robak T, B\u0142asi\u0144ska-Morawiec M, B\u0142o\u0144ski J, et al.. 2-Chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland. Eur J Haematol. 1999, 62:49-56. 10.1111\/j.1600-0609.1999.tb01114.x","journal-title":"Eur J Haematol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-1752","article-title":"Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia","volume":"19","author":"Kreitman RJ","year":"2013","unstructured":"Kreitman RJ, Wilson W, Calvo KR, et al.. Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia. Clin Cancer Res. 2013, 19:6873-81. 10.1158\/1078-0432.CCR-13-1752","journal-title":"Clin Cancer Res"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-018-0093-8","article-title":"Clinicopathologic and molecular features in hairy cell leukemia-variant: single institutional experience","volume":"31","author":"Angelova EA","year":"2018","unstructured":"Angelova EA, Medeiros LJ, Wang W, et al.. Clinicopathologic and molecular features in hairy cell leukemia-variant: single institutional experience. Mod Pathol. 2018, 31:1717-32. 10.1038\/s41379-018-0093-8","journal-title":"Mod Pathol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009688","article-title":"Phase 2 study of ibrutinib in classic and variant hairy cell leukemia","volume":"137","author":"Rogers KA","year":"2021","unstructured":"Rogers KA, Andritsos LA, Wei L, et al.. Phase 2 study of ibrutinib in classic and variant hairy cell leukemia. Blood. 2021, 137:3473-83. 10.1182\/blood.2020009688","journal-title":"Blood"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112138-20220414-00274","article-title":"Clinical and molecular characteristics and prognosis of classical hairy cell leukemia and hairy cell leukemia variant (Article in Chinese)","volume":"62","author":"Wei C","year":"2023","unstructured":"Wei C, Jin XX, Cai H, Wang X, Zhuang JL, Zhou DB. Clinical and molecular characteristics and prognosis of classical hairy cell leukemia and hairy cell leukemia variant (Article in Chinese). Zhonghua Nei Ke Za Zhi. 2023, 62:416-21. 10.3760\/cma.j.cn112138-20220414-00274","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00760-z","article-title":"Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia","volume":"12","author":"Ravandi F","year":"2022","unstructured":"Ravandi F, Kreitman RJ, Tiacci E, et al.. Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia. Blood Cancer J. 2022, 12:165. 10.1038\/s41408-022-00760-z","journal-title":"Blood Cancer J"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/183855-a-case-of-hairy-cell-leukemia-variant-literature-analysis-with-focus-on-unmet-needs","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:09:16Z","timestamp":1707509356000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/183855-a-case-of-hairy-cell-leukemia-variant-literature-analysis-with-focus-on-unmet-needs"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,15]]},"references-count":43,"URL":"https:\/\/doi.org\/10.7759\/cureus.47085","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,15]]}}}